Anidulafungin is a type of medicine called an antifungal. It's used to treat infections caused by a fungus called Candida. It works by stopping the fungus from growing.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Anidulafungin, sold in the US as Eraxis, is an antifungal medicine given through a vein to treat serious infections caused by Candida, a yeast that normally lives harmlessly on the skin and in the gut. It is approved for candidemia (Candida in the bloodstream) and for Candida infections inside the abdomen, such as an abscess or peritonitis (infection of the lining of the abdominal cavity), in adults and in children 1 month and older. It is also approved for Candida infection of the esophagus, the tube that carries food to the stomach, in adults. Candida bloodstream infections can be life-threatening and usually develop in people who are already in the hospital, especially those with a central IV line, recent surgery, broad-spectrum antibiotics, intravenous nutrition or cancer. Anidulafungin belongs to a group of antifungals called echinocandins, and nearly all published treatment guidelines recommend an echinocandin as the first drug for invasive Candida infections in critically ill adults. It has not been studied for Candida infections of the heart valves, bone or brain, and the right dose for infections that have spread to the eye or brain is not established, so other treatment plans are used there.
Fungal cells are surrounded by a rigid cell wall that human cells do not have. One of its main building blocks is a sugar chain called beta-glucan, made by an enzyme called glucan synthase. Anidulafungin blocks that enzyme, so the yeast cannot build or repair its wall properly and the cells are damaged. Because the target exists only in fungi, the drug can act on Candida without affecting the same process in the body's own cells. It works against the Candida species that cause most of these infections, including Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis. Some Candida strains have developed reduced sensitivity to echinocandins, which is one reason the lab tests the organism from a culture and treatment may be adjusted once results return.
Anidulafungin is given only as an intravenous (IV) infusion, usually in a hospital. There is no pill form. Treatment starts with a larger loading dose on the first day, followed by a smaller dose once a day. The infusion runs slowly, typically about an hour and a half for a usual adult daily dose, because a faster rate makes infusion reactions more likely. Children receive a dose based on their weight. For a bloodstream infection, treatment generally continues for at least 14 days after the last blood culture that grows Candida, so the total length depends on how quickly the infection clears. For esophageal infection, treatment lasts at least 14 days and at least 7 days after symptoms resolve. The dose does not need to change for kidney disease, including people on dialysis, or for liver disease. Dialysis does not remove the drug, so it can be given without regard to dialysis timing.
In adults treated for bloodstream infections, the most commonly reported problems were low potassium levels, nausea, diarrhea, vomiting, fever, trouble sleeping and low blood pressure. Many of these also reflect how ill people with these infections already are, which is why the care team checks blood work, including potassium, during treatment. Some people react during the infusion with flushing, itching, hives, a rash, wheezing, breathlessness or a drop in blood pressure. Tell the nurse right away if any of these start during an infusion; slowing or stopping it usually helps. Serious allergic reactions, including anaphylaxis with shock, have been reported, and the drug is stopped if one occurs. Anidulafungin can raise liver test results, and rare cases of hepatitis or liver failure have occurred in very ill people taking many medicines, although it is not clear the drug caused them. Liver tests are monitored, and yellowing of the skin or eyes, dark urine or unusual tiredness should be reported to the care team.
Anidulafungin should not be used by anyone who has had an allergic reaction to it or to other echinocandins, such as caspofungin or micafungin. It also should not be given to people with known or suspected hereditary fructose intolerance, a rare inherited condition in which the body cannot process fructose, because the product contains fructose and can trigger a dangerous metabolic crisis with very low blood sugar. Because this condition may not yet be diagnosed in young children, the care team asks whether a child has had nausea, vomiting or belly pain after eating fruit or sweets. It is not approved for infants younger than 1 month. It contains polysorbate 80, an inactive ingredient that has caused serious harm in low-birth-weight newborns at high doses. Animal studies suggest it could harm a developing baby, and there are no human data, so anyone who is pregnant or could be pregnant should discuss this with the treating team. It is not known whether it passes into breast milk. Anidulafungin has few drug interactions. It is not processed by the liver enzymes that cause many antifungal interactions, and studies found no need to change doses when it was given with transplant medicines such as cyclosporine and tacrolimus or with the antibiotic rifampin.
Treatment usually begins in the hospital, often before the lab has fully identified the yeast. Once the species and its sensitivity to antifungals are known, the team may continue anidulafungin or switch to a different drug. Repeat blood cultures show when the bloodstream has cleared, which sets the treatment clock. Many people move to an oral antifungal, most often fluconazole, after their condition is stable, they no longer have a fever and their blood cultures are negative, so they can finish treatment at home. In the main adult trial, about three in four people treated with anidulafungin had a successful response by the end of IV treatment, compared with about six in ten treated with fluconazole, but outcomes depend heavily on the underlying illness. For esophageal infection, symptoms often improve within days, but in its main trial the infection came back within two weeks after treatment in about half of people, much more often than with oral fluconazole. People with HIV may need ongoing preventive antifungal treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Anidulafungin, what you've noticed, or ask the community a question.